Phase 3 Trials and FDA on the Chopping Block
March 4, 2013 | Federal cost cutting measures should look no farther than the FDA, argues an op ed in Bloomberg. First on the chopping block: Phase 3 clinical trials. Though the system has served us well in the past, the authors argue that the system not only costs too much money--but it may be causing more harm than good. Bloomberg In the Pipeline blog author, Derek Lowe, comments on the promises and problems of the approach. In the Pipeline.
Click here to log in.
Text Only 2000 character limit
Page 1 of 1